Takatsuki, Japan

Kiyosei Iio


Average Co-Inventor Count = 11.9

ph-index = 2

Forward Citations = 18(Granted Patents)


Company Filing History:


Years Active: 2007-2011

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Kiyosei Iio: Innovator in Pharmaceutical Compounds

Introduction

Kiyosei Iio is a notable inventor based in Takatsuki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target various diseases. With a total of 3 patents to his name, Iio's work has the potential to impact the treatment of serious health conditions.

Latest Patents

One of Iio's latest patents is focused on a piperazine compound that serves as an HCV polymerase inhibitor. This invention relates to a compound represented by a specific formula, which is effective in showing anti-HCV activity. The compound is useful as an agent for the prophylaxis or treatment of hepatitis C. Another patent involves compounds and pharmaceutical compositions that are beneficial in treating or preventing metabolic and cell proliferative diseases. This invention provides compounds that modulate the activity of proteins involved in lipid metabolism and cell proliferation.

Career Highlights

Kiyosei Iio is currently associated with Japan Tobacco Inc., where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to developing effective treatments for complex health issues.

Collaborations

Iio has collaborated with notable coworkers, including Masahiro Tanaka and Brian M Fox. These partnerships have likely contributed to the advancement of his research and the successful development of his patents.

Conclusion

Kiyosei Iio is a prominent inventor whose work in pharmaceutical compounds demonstrates his dedication to improving health outcomes. His innovative patents reflect a deep understanding of complex biological processes and a commitment to addressing significant medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…